Statistical analyses
This dose-expansion study planned to initially enrol 20 patients in each tumour-specific arm. The probability of observing at least one responder was calculated to be approximately 88% in each dose-expansion arm (Data for each arm in this study were analysed independently. For PFS and OS, median durations and event-free rates at various timepoints were estimated using the Kaplan–Meier method: for medians and other quartiles, 95% confidence intervals (CIs) were estimated using the Brookmeyer and Crowley method; for event-free rates, 95% CIs were estimated using the Kaplan–Meier method and the Greenwood formula. Patients who remained alive before data cutoff or discontinuation of the study were censored at the last date the subject was known to be alive. DoR analyses only included patients who responded to treatment, with the same censoring rules used for PFS, and Kaplan–Meier curves were used to estimate median DoR and 95% CIs. The incidence of treatment-emergent AEs (TEAEs), incidence of ADAs, laboratory test results, vital signs, pharmacokinetic parameters, and their changes from baseline were summarised using descriptive statistics. All safety analyses were performed by arms and by the total combination of cohorts in the safety analysis set. All calculations and analyses were conducted using SAS version 9.2 or higher. The study was not powered to detect statistical significance.